Lytex6 mg/15 ml

Lytex 6 mg/15 ml is a clinically proven mucolytic and expectorant agent widely used to manage respiratory conditions characterised by excessive, thick, or viscid mucus that is difficult to clear. By thinning and loosening mucus secretions throughout the airways, it facilitates expectoration and improves breathing comfort.

Approved Indications

• Productive cough: Lytex 6 mg/15 ml is prescribed to relieve wet or productive cough by reducing the viscosity of mucus, making it easier to cough up and clear from the airways.
• Acute and chronic bronchitis: Effective in both acute flare-ups and long-term management of chronic bronchitis, where excessive mucus production obstructs airflow and causes persistent cough and breathlessness.
• Upper and lower respiratory tract inflammatory disorders: Used in the symptomatic management of inflammatory conditions affecting both the upper and lower respiratory tracts associated with abnormally thick or sticky mucus secretions.
• Rhinopharyngeal tract diseases: Provides mucolytic relief in inflammatory conditions of the nose and throat, including:
  • Laryngitis – inflammation of the voice box causing hoarseness and cough
  • Pharyngitis – throat inflammation causing soreness and difficulty swallowing
  • Sinusitis – inflammation of the sinuses leading to congestion and facial pressure
  • Rhinitis – inflammation of the nasal lining causing runny nose and congestion
• Asthmatic bronchitis and bronchial asthma with thick expectoration: Helps reduce the burden of viscid mucus in asthmatic patients, improving airway clearance and reducing the severity of respiratory distress during episodes.
• Bronchiectasis: Assists in managing the excessive mucus buildup in permanently damaged and widened airways, reducing the risk of secondary bacterial infection and improving drainage.
• Chronic pneumonia: Used as a supportive mucolytic agent in chronic pneumonia to aid in the clearance of secretions from the lungs and facilitate recovery.

Lytex 6 mg/15 ml is intended for symptomatic relief and should always be used as part of an overall treatment plan directed by a registered physician.

Lytex 6 mg/15 ml is the active metabolite of bromhexine, and clinical research has demonstrated that it possesses a significantly greater bronchosecretolytic potency than its parent compound. Its therapeutic effectiveness is the result of several complementary mechanisms that collectively reduce respiratory mucus viscosity, improve airway patency, and provide anti-inflammatory protection.

Mechanism of Action

• Mucolytic activity via hydration: Ambroxol improves sputum rheology through a hydrating mechanism. It stimulates the serous glands of the bronchial mucosa to secrete a more watery fluid, which dilutes and thins the thick mucus layer coating the airways. This liquefaction of mucus makes it significantly easier to expel through coughing, thereby reducing dyspnoea (difficulty breathing) and chest tightness.
• Stimulation of pulmonary surfactant synthesis: Ambroxol stimulates the type II alveolar pneumocytes (specialised lung cells) to increase their production of pulmonary surfactant — a complex mixture of phospholipids and proteins that reduces surface tension within the alveoli. By maintaining alveolar stability, surfactant prevents lung collapse and supports optimal gas exchange. This mechanism is particularly relevant in neonates and premature infants at risk of respiratory distress syndrome (RDS).
• Mucociliary clearance enhancement: The drug activates ciliated epithelial cells lining the respiratory tract, increasing the frequency and co-ordination of ciliary beat. This improves the mucociliary escalator — the natural mechanism by which mucus and inhaled particles are transported upward out of the lungs — aiding in the removal of secretions and pathogens.
• Anti-inflammatory properties: Ambroxol exerts meaningful anti-inflammatory effects by inhibiting the release of cellular cytokines (inflammatory signalling molecules) and the production of arachidonic acid metabolites (prostaglandins and leukotrienes). This reduces localised airway inflammation, decreases mucosal oedema, and contributes to overall symptomatic relief in acute respiratory infections.
• Reduction of bronchial hyperreactivity: Ambroxol has been shown to reduce bronchial hyperreactivity, which is the tendency of the airways to overreact to irritants or triggers. This property is particularly beneficial in patients with asthmatic bronchitis or bronchial asthma with thick secretions.
• Improvement of airway patency in COPD: In patients with chronic obstructive pulmonary disease (COPD), Ambroxol traditionally improves airway patency by reducing mucus obstruction and supporting better airflow through the bronchial tree.

Pharmacokinetics

Lytex 6 mg/15 ml is well absorbed from the gastrointestinal tract following oral administration. It undergoes hepatic metabolism and is excreted primarily via the kidneys. The drug distributes widely into lung tissue, where it achieves therapeutic concentrations that support its mucolytic and surfactant-stimulating effects.

While Lytex 6 mg/15 ml has a generally favourable drug interaction profile, one clinically important interaction must be observed, and patients should always inform their physician of all medications they are currently taking.

Key Drug Interaction

• Antitussive agents (cough suppressants) – e.g., Codeine, Dextromethorphan: Lytex 6 mg/15 ml must not be taken simultaneously with cough suppressants. Ambroxol works by thinning and loosening mucus, which must then be expelled through the cough reflex. If an antitussive drug is taken at the same time, the cough reflex is suppressed, preventing the expectoration of the liquefied mucus. This can lead to accumulation of secretions in the bronchi, increasing the risk of mucus pooling, secondary infection, and respiratory complications.

Other Potential Interactions to Discuss with Your Physician

• Antibiotics (e.g., amoxicillin, cefuroxime, erythromycin, doxycycline): Ambroxol may enhance the penetration of certain antibiotics into bronchial secretions and lung tissue. This can be clinically advantageous in respiratory infections, but should be noted by the prescribing physician when designing combination therapy.
• Other mucolytic agents: Concurrent use of multiple mucolytic drugs is generally unnecessary and should be avoided unless specifically directed by a physician.

Always consult a registered physician before combining Lytex 6 mg/15 ml with any other medication to avoid potential adverse interactions.

Lytex 6 mg/15 ml is generally well tolerated across all age groups when used at recommended doses. The majority of side effects are mild, transient, and gastrointestinal in nature. However, rare but serious hypersensitivity reactions have been reported and must be recognised promptly.

Gastrointestinal Side Effects (Occasional)

• Epigastric pain: Some patients may experience discomfort or pain in the upper abdomen (epigastric region). Taking Ambroxol after meals significantly reduces this risk.
• Stomach fullness or bloating: A sensation of stomach overfill or abdominal distension may occur, particularly with higher doses.
• Nausea and vomiting: Mild nausea has been reported; vomiting is uncommon but may occur in sensitive individuals.
• Diarrhoea: Loose stools or diarrhoea may occasionally develop, especially in young children receiving the syrup formulation.

Allergic and Hypersensitivity Reactions (Rare)

• Skin rash (eruption): Mild to moderate skin rashes have been reported in rare cases and may indicate a hypersensitivity reaction to the drug.
• Urticaria (hives): Raised, itchy welts on the skin surface may develop as an allergic response, typically resolving after discontinuation of the drug.
• Angioneurotic oedema (angioedema): A rare but potentially serious allergic reaction involving deep tissue swelling, most commonly affecting the face, lips, tongue, throat, and extremities. Throat involvement can compromise the airway and requires immediate emergency medical care.

When to Seek Medical Attention

Stop taking Lytex 6 mg/15 ml and seek immediate medical attention if you develop swelling of the face, throat or tongue, difficulty breathing, widespread skin rash, or any other sign of a serious allergic reaction.

Pregnancy

Formal teratogenicity and foetal toxicity studies conducted with Lytex 6 mg/15 ml have not demonstrated any harmful effects on the developing foetus. No structural deformities or adverse developmental outcomes attributable to the drug have been reported in the published literature with normal therapeutic use.

Despite this reassuring preclinical profile, it is strongly advised not to use Lytex 6 mg/15 ml during pregnancy, particularly during the first trimester, when the developing embryo is most vulnerable to external agents and organogenesis (organ formation) is occurring. The safety of Ambroxol in human pregnancy has not been conclusively established through adequate and well-controlled clinical trials. Its use during the second and third trimesters should only be considered when clearly necessary and when the potential benefit to the mother outweighs any potential risk to the foetus — and always under the direct supervision of a physician.

Lactation (Breastfeeding)

The safety of Lytex 6 mg/15 ml during breastfeeding has not been fully established. It is not known with certainty whether the drug is excreted into human breast milk in clinically significant quantities. As a precaution, breastfeeding mothers should consult their physician before using this medication. If its use is considered medically essential, the physician may advise temporarily discontinuing breastfeeding during the course of treatment.

While Lytex 6 mg/15 ml is generally safe for most patients, the following precautions should be carefully observed to ensure its safe and effective use:

• Gastric and duodenal ulceration: Ambroxol should be given with particular caution to patients with a history of peptic ulcer disease, including active or recently healed gastric or duodenal ulcers. Taking the drug after meals can reduce the risk of gastrointestinal irritation. Patients should report any worsening of upper abdominal symptoms to their physician promptly.
• Convulsive (seizure) disorders: Patients with a history of epilepsy or other convulsive disorders should use Lytex 6 mg/15 ml with caution and under medical supervision.
• Hepatic (liver) impairment: Ambroxol is metabolised in the liver. In patients with significant hepatic impairment, drug metabolism may be reduced, leading to higher plasma concentrations and an increased risk of adverse effects. Dose adjustment or more frequent monitoring may be required.
• Renal (kidney) impairment: Ambroxol and its metabolites are primarily excreted by the kidneys. Patients with moderate to severe renal insufficiency should use this medication with caution, as impaired renal clearance may lead to accumulation of the drug and its metabolites.
• Adequate fluid intake: Patients are encouraged to drink sufficient water and fluids during treatment with Ambroxol. Adequate hydration supports the mucolytic action of the drug by further diluting bronchial secretions, making them easier to expectorate.
• Avoid concurrent antitussives: As detailed in the drug interactions section, antitussive (cough-suppressant) medications must not be used at the same time as Ambroxol, as this combination may cause retention of liquefied mucus in the lungs.
• Paediatric use in very young infants: Ambroxol paediatric drops should be used in very young infants (0–6 months) only under close medical supervision, with strict adherence to the prescribed dose.
• Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis: Although extremely rare, cases of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported in patients taking mucolytic agents. If a patient develops progressive skin blistering, peeling, or mucosal involvement, Ambroxol should be discontinued immediately and specialist care sought.

Specific published data on the clinical consequences of Lytex 6 mg/15 ml overdose in humans is limited. The drug has a wide therapeutic index and is generally considered to have a low overdose risk at doses used in standard clinical practice. However, accidental or intentional ingestion of significantly higher doses may be expected to produce an exaggeration of the drug's known pharmacological and gastrointestinal effects.

Possible Symptoms of Overdose

• Nausea and vomiting
• Excessive salivation
• Significant abdominal discomfort or pain
• Diarrhoea
• Agitation or restlessness (in children)
• Hypotension (low blood pressure) in severe cases

Management of Overdose

Treatment is primarily symptomatic and supportive. In the event of suspected overdose:

• Do not attempt to induce vomiting unless specifically instructed by a healthcare professional.
• Contact the nearest poison control centre or go to the emergency department of the nearest hospital immediately.
• Bring the medication packaging with you to assist medical staff in identifying the drug and dose ingested.
• Provide supportive care as directed by the treating physician, which may include IV fluids, monitoring of vital signs, and symptomatic management.

• Protect from light: Store in the original opaque packaging or a light-resistant container. Do not expose to direct sunlight or prolonged artificial light, as light can degrade the active ingredient over time.
• Store in a dry place: Keep away from areas of high humidity, such as bathrooms or kitchens. Moisture can accelerate the breakdown of the medication and compromise its effectiveness.
• Temperature: Store at a temperature not exceeding 30°C. Avoid storage in locations subject to excessive heat, such as inside a car, near a stove, or in direct sunlight.
• Keep out of the reach of children: All formulations of Lytex 6 mg/15 ml — including drops, syrup, and capsules — must be stored securely and out of the sight and reach of children to prevent accidental ingestion.
• Syrup and drops after opening: Once opened, syrup and paediatric drop formulations should be used within the period specified on the label. Do not use if the liquid has changed colour, become cloudy, or shows visible particles.
• Do not use after expiry: Always check the expiry date printed on the bottle and packaging before administering. Discard any expired medication through appropriate pharmaceutical waste disposal channels — do not flush down the drain or throw in household rubbish.

Paediatric Use

Lytex 6 mg/15 ml is widely used in children and infants and is available in age-appropriate formulations including paediatric drops (6 mg/ml) and syrup (15 mg/5 ml) to facilitate accurate dosing by body weight and age. It is one of the most commonly prescribed mucolytic agents for respiratory conditions in the paediatric population in Bangladesh.

Use in infants under 6 months must be approached with caution and should only be carried out under direct medical supervision, with careful dose measurement using the calibrated dropper provided. Parents should be counselled on the correct administration technique and the importance of not exceeding the prescribed dose.

Geriatric Use

Older adults may use Lytex 6 mg/15 ml, but age-related declines in hepatic and renal function should be taken into account. Elderly patients are at greater risk of drug accumulation due to reduced clearance, and physicians may consider starting at the lower end of the dose range. Monitoring for gastrointestinal tolerance is also advised in this population, given the higher prevalence of peptic ulcer disease and polypharmacy.

Renal Impairment

Patients with moderate to severe chronic kidney disease should use Ambroxol with caution. In cases of significant renal insufficiency, reduced dosing frequency or lower doses may be appropriate to prevent accumulation of the drug and its metabolites.

Hepatic Impairment

Since Ambroxol undergoes hepatic metabolism, patients with clinically significant liver disease may have reduced drug clearance. These patients should be monitored more closely and dose adjustments may be necessary based on the severity of hepatic impairment.

Neonatal and Premature Infant Use

Ambroxol has been studied for its role in stimulating surfactant production in premature neonates at risk of neonatal respiratory distress syndrome (NRDS). However, use in this age group must be exclusively managed by a specialist neonatologist in a clinical setting.